Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

(2018) François-Clément Bidard et al.   JNCI-Journal of the National Cancer Institute

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

(2018) François-Clément Bidard et al.   JNCI-Journal of the National Cancer Institute

Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130CAS/Src inhibition by eribulin

(2017) Nicholas F. Dybdal-Hargreaves et al.   Oncotarget

Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer

(2016) Kyung-A Hyun et al.   Oncotarget

Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples

(2016) Priya Gogoi et al.   PLoS One

Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer

(2015) M. Mego et al.   BMC CANCER

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer

(2015) Hara Polioudaki et al.   BMC CANCER

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial

(2015) C. Helissey et al.   CANCER LETTERS

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy

(2015) W. Onstenk et al.   MOLECULAR CANCER THERAPEUTICS

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Circulating Tumor Cell Enumeration with a Combination of Epithelial Cell Adhesion Molecule- and Cell-Surface Vimentin-Based Methods for Monitoring Breast Cancer Therapeutic Response

(2014) A. Satelli et al.   CLINICAL CHEMISTRY

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

(2014) François-Clément Bidard et al.   LANCET ONCOLOGY

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

(2013) M. Yu et al.   SCIENCE

Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition

(2012) Tobias M Gorges et al.   BMC CANCER

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

(2011) Robert Königsberg et al.   ACTA ONCOLOGICA

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

(2011) J.- Y. Pierga et al.   ANNALS OF ONCOLOGY

CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes

(2011) Bianca Mostert et al.   CANCER LETTERS

Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

(2011) A. J. Armstrong et al.   MOLECULAR CANCER RESEARCH